Infusion of donor lymphocytes in leukemia patients relapsed after bone marrow transplantation is successful if T cells of recipients are of donor origin by Wiel-van Kemenade, E. van de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/27126
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
1094 Experimental Hematology vol. 24 (1996)
INFUSION OF DONOR LYMPHOCYTES IN LEUKEMIA PATIENTS 
RELAPSED AFTER BONE MARROW TRANSPLANTATION IS 
SUCCESSFUL IF T CELLS OF RECIPIENTS ARE OF DONOR ORIGIN
Ellv van de Wiel-van Ketnenadc. Harry Dolstra, Anton Schattenberg, Frans 
Maas, Hanny Fredrix, Frank Preijers, Brigit Bär, Ewald Mensink, Carl G. 
Figdor, and Theo de Witte. Division of Hematology, University Hospital 
Nijmegen, The Netherlands 
Infusion of donor lymphocytes is increasingly used to treat patients with 
leukemic relapse after allogeneic bone marrow transplantation. Significant 
numbers of patients with chronic myeloid leukemia respond lo this therapy, 
usually accompanied by graft-versus-host disease. Only a minority of patients 
with acute myeloid and no patients with acute lymphoid leukemia respond to 
donor lymphocyte infusion. Direct correlation of nonresponsiveness with the 
absence of graft-versus-host disease suggests that infused lymphocytes arc 
neither reactive to the leukemic cells nor to normal tissue of these patients. In an 
attempt to answer the question why some patients respond while others do not, 
we determined the genetic origin of T cells present in 19 relapsed patients at the 
time of donor lymphocyte infusion. All patients who had T cells of donor origin, 
attained complete remission. In contrast, all but two patients with T cells 
predominantly of recipient origin failed to respond. T cells of responding 
patients showed cytotoxicity in vitro against target cells of recipient origin 
including leukemic cells. T cells of nonrespondin^ patients did not show 
cytotoxicity in vitro against target cells of recipient origin. These findings 
demonstrate that the origin of T cells at the time of relapse is an important 
prognostic parameter. If T cells are of donor origin, complete remission occurs 
upon infusion of donor lymphocytes. This led us to hypothesize that autologous 
T cells of nonresponding patients may destroy infused donor lymphocytes, thus 
explaining treatment failure.
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ADOPTIVE IMMUNOTHERAPY WITH RECOMBINANT HUMAN IL-2 
(rHuIL-2) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) 
FOR HIGH-RISK NEUROBLASTOMA (HR-NB).
A. Pesslon. A, Prctc, *F. Locaiclli, P. Alvisi,<i00A. Garavenla, ***C. Messina, S. Picrinelti, 
*FJ8onc|ti, **L. Cordero, °C. Favre, °°A. Arrighini, R.Rondctli, 000B. De Bemardi, G. Paolucci. 
Pediatric Department of Bologna, *Pavia, **Tarino, ***Padava, °Pisa,“Brescia,0WGetwva4laly,
Objective. A phase IIAll trial, with low doses of rHulL-2 over a prolonged 
period of time, was carried out. The aim of the study was to evaluate 
immunomodulatory effects induced by IL-2 and its potential role in eradication or 
control minimal residual disease (MRD) in NB after high dose chemotherapy 
(HDCT) followed by ASCT.
Patient and method. From 1/92 to 2/96, 25 pts with HR-NB (I in Til CR, 2 in 
II VGPR, 2 in II CR, 13 in I VGPR, 7 in I RC) received rHIL-2 (Proleukin, 
Aldesleuchina), after a median (min-max) time of 91 (43-153) days from ASCT. 
Treatment schedule consisted of 2 cycles of 24-h iv for 5 days (2-4-6-S-8 
MU/sqm/d respectively) followed by 11 monthly and 6 bimonthly cycles of rHuIL- 
2 administered sc for 5 d (2-4-4-4 MU/sqm/d), for a total of 18 cycles/pts. 
Results. Were administered 223 cicles of therapy. Immunological analysis 
globally evidenced an increment of NK and activated T cells number. Iperpirexm 
(25/25) and trombocytopenia (4/25), were the only rHuIL-2 dependent toxicity 
observed during iv or sc administration. 1 pt stopped the iv phase for gram- sepsis, 
1 pi reduced iv dosage because a feverish convulsion. 20/25 pts are alive and well 
with a median (min-max) follow up of 10 (2-50) months, 5/25 pts relapsed with a 
median (min-max) time of 13 (6-41) months, only one of these pts died for PD, 35 
months after ASCT. Overall EFS at 3 years was 33%.
Conclusion. Adoptive immunotherapy with low doses of rHIL-2 is feseable and 
seems to be effective in inducing activated immunocompetent cells proliferation and 
in controlling MRD after HDCT and ABMT in HR-NB.
(Supp. by Associazione Italiana Neuroblastoma)
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THE RECOMBINANT GAMMA-INTERFERON AND RETRO- 
PLACENTAR POUBIOLIN IN SYSTEMIC VASCULITIS IMMUNO­
THERAPY. V.Chopyak*. Lviv Medical Institute, Regional Diagnostic Cen­
ter, Regional Clinical Hospital, Lviv, Ukraine.
Clinico-immunolngically 27 systcmic vasculitis patients (SV) -  were ob­
served. In cultural immunologic investigation -  their immunocompetent cells 
sensitivity to Gamma-intcrferon (Gl) and retroplacentar polîbîoi in (RP)- was 
estimated. Complex immunothernpy GI and RP -  was applied to this patient 
group according lo special scheme during one year. The control group made 
43 patients with SV, who got traditional glucocorticoid therapy. The immu­
nologic and hemocoagulative monitoring -  was carried out in patients during 
a year. After 4 treatment weeks -  hyperimmunocomplexemia lowering, ph- 
agocytosis-menibrane and fermentative properties improvement, a 2-mncro- 
globulin level and DR-lymphocytes number increase -  was estimated. The 
immunologic values of dynamic -  less then a year period shoved, the 
antiintimal antibodies level, fibronectin -  lowering, pj-microglobulins status 
stabilisation, specific lymphocytes sensibilisation lowering to intimai anti­
gen, CD4/CD8 ratio normalisation -  was estimated. Thus, the applied immu­
notherapy leads to mutual balancing of clinic-immuno-hemostasiological sta­
tus in systemic vasculitis patients.
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INDUCTION OF SPECIFIC CYTOTOXIC T CELLS AGAINST LEUKEMIC 
CELL LINES USING DENDRITIC CELLS FROM CORD BLOOD CD34+ 
CELLS. Fujii S*. Fuiimoto K*. Kawakita M The Second Department of Internal 
Medicine, Kumamoto University School of Medicine, Kumamoto, Japan.
Dendritic cell (DC) is the most powerful antigen-presenting cells for immune 
responses. Recently, methods has been established for in vitro propagation of 
human DCs from bone marrow. Thus expanded DCs can afford promise of 
improving the efficacy of immunotherapy for cancers. It is well known that cord 
blood (CB) cells contain tvaive T cells and a small number of cytotoxic T cell 
precursors. Successful transplantation of HLA-mismatched CB cells without 
severe GVHD may support this fact. To develop an unique anti-tumor immuno­
therapy, we have induced tumor-specific cytotoxic T cells from naive CB T cells 
using autologous DCs. After CD34+ cells were isolated from CB with immuno- 
magnetic beads, the remainder containing T was immediately preserved in liquid 
N;j. CD34+ cells were cultured with GM-CSF(100ng/ml) and TNF-a (2.5ng/mt) 
for 4d, resulting m marked expansion of DCs that were readily identified by then- 
distinctive morphologies and phenotypes. Then the cells were pulsed for another 
7d with each of 10 Gy-irradiated leukemic cell line, such as K562, K562 with 
positive class I antigen, U937 or HUT 102. K562-class 1+ cells were prepared hy 
the stimulation of original K562 cells with IFN-y and TNF-a. On day 11. CD4+ 
and CD8+ cells obtained from the remainder of original CB cells were added to the 
cultured DCs (CD4:CD8;=8:2). After 7d expansion, the naive T cells from CB 
developed remarkable cytotoxic activities against specific leukemic cells, For 
example, 40% cytolysis in K562-class 1+ cells (E/T ratio=50;l) by 51Cr-teleuse 
assay. Although the expanded T cells may contain some alloreactive CTLs, this 
approach may be useful for tumor vaccine induction, i.e., naive T cells could be 
activated by DCs pulsed with tumor cells or tumor-specific antigens, thus 
generating tumor-specific cytotoxic T cells. Such an approach may enhance the 
therapeutic value of CB transplantation, in which one could expect not only a 
minimal GVHD but also specific GVL reactions.
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THE COMBINED IMMUNOTHERAPY OF HERPETIC INJURIES IK 
PATIENTS WITH HEMORRHAGIC V A SC U U IIE S . N .V y n o g ra d , 
I . V y n o g r a d .  V«Chopyak.* V .O r e l .  B .B u r a c h i n s k y .  
L . 2 a s t a w n a > L v i v .  S l u  ~of~~~RpidomloIogy, L v iv  M e d ic a l  
In s t iV u fceT liV iv  R e g i o n a l  C l i n i c a l  H o s p i t a l ,  L v iv ,  
U k r a i n e .
The I n v e s t i g a t i o n  o f  c o m b in e d  t h e r a p y  e f f a c t i v e n e s s  
o f  26 p a t i e n t s  w i t h  h e m o r r h a g i c  v a s c u l i t i s  w i t h  . 
h e r p e t i c  i n j u r i e s  was c a r r i e d  o u t .  R e c o m b in a n t  c \ p -  
i n t e r f e r o n  ( H e a l d i r a n ,,S a n i t a s " ) l a c y c l o v i r C Z o v i r a x ;  
W e l lc o m e ) ,  p l a c a n t a r  im m u n o g lo b u l in  (^Biopharm*) w a re  
a p p l i e d .  Tha v i r u s o l o g i c  d i a g n o s t i c s  w as c a r r i e d  o u t  
b y  m e th o d  o f  d i r e c t  im m u n o f lu o r e s c e n c e  o f  s m e a rs  -  
i m p r i n t s  f r o m  p l a o e  o f  i n j u r y  a n d  d e t e c t i o n  o f  a n t i
?e n s  b y  ELISA. I n  I 2  p a t i e n t s  H e r p e s  s i m p l e x  v i r u s  HSVT) - o f  A g r o u p ,  i n  1 4  - V a r i c e l l a  z o s t e r ( V Z )  - o f  
B g r o u p .E v e r y d a y  a c y c l o v i r  i n j e c t i o n  ( 2 0 0 , 0  x. J t i r a e s
-  10  d a y s ) , y a a l d i r o n e  ( I  mmol MO t i m e s  -  8 d a y s ) ,  
p l a c e r v t a r  im m u n o g lo b u l in  (25 mg/Kg x  o n ce  i n  2 days
-  20 d a y s )  c o n t r i b u t e d  t o  m ore e a s y  c l i n i c a l  f l o w .
The a b o r t i v e  fo rm  was e s t i m a t e d  i n  64-,?% o f  A g r o u p  
a n d  4 7 , 4 $  o f  B g r o u p .  The m a in  s y m p to m a t i c a  d e c r e a s e  
was e s t i m a t e d  i n  62 ,9%  a n d  46 ,8%  i n  A a n d  B g r o u p s
c o r r e s p o n d i n g l y • ^ b e  t r e a t m e n t ,  b e g u n  i n  p r o d r o m a l
p e r i o d  o f  h s r p e s - p o s i t i v e  p a t i e n t s  w i t h  h e m o r r h a g ic  
v a s c u l i t i s  w as m o s t  e f f e c t i v e  a n d  c o n t r i b u t e d  t o  
m a in  d i s e a s e  s t a b i l i s a t i o n .
